Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors — Zheng-Yong Wan (2015) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
Shared by
De Clercq Erik
KU Leuven
Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
Article
2015
en
Authors
+10 more
ZW
Zheng-Yong Wan
JY
Jin Yao
YT
Yuan Tao
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2013
Discovery of Piperidine‐Linked Pyridine Analogues as Potent Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors
Xuwang Chen
,
Yuanyuan Li
,
Shufang Ding
,
Jan Balzarini
,
Christophe Pannecouque
,
De Clercq Erik
,
Huiqing Liu
,
Xinyong Liu
Article
2015
Hybrid chemistry. Part 4: Discovery of etravirine–VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors
Zheng-Yong Wan
,
Yuan Tao
,
Ya-Feng Wang
,
Tian-Qi Mao
,
Hong Yin
,
Fen‐Er Chen
,
Hu‐Ri Piao
,
De Clercq Erik
,
Dirk Daelemans
,
Christophe Pannecouque
Article
2015
Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif
Wenxin Li
,
Xiao Li
,
De Clercq Erik
,
Peng Zhan
,
Xinyong Liu
Article
2014
Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach
Jun Wang
,
Peng Zhan
,
Zhenyu Li
,
Huiqing Liu
,
De Clercq Erik
,
Christophe Pannecouque
,
Xinyong Liu
Article
2025
Structure-Based Drug Design Yields Diarylpyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
Zhenzhen Zhou
,
Jie Guo
,
Xin Li
,
Jinyuan Wu
,
De Clercq Erik
,
Christophe Pannecouque
,
Peng Zhan
,
Dongwei Kang
,
Xinyong Liu
Discussion(0)
No comments yet. Be the first to comment.